ABSTRACT The first three enzymes of pyrimidine biosynthesis (carbamoyl-phosphate synthetase, aspartate carbamoyltransferase, and dihydro-orotase) are carried on a multifunctional protein in mammalian cells and are on separate proteins in bacteria. A plasmid containing a cDNA sequence corresponding to 80% of a hamster mRNA for this protein was transformed into Escherichia coli mutants lacking aspartate carbamoyltransferase (pyrB) or dihydro-orotase (pyrC). Only pyrB transformants were able to grow in the absence of uracil. Plasmid recovered from primary transformants was similar in size to the original plasmid and could yield prototrophs after secondary transformation of E. coli pyrB mutants. When cell extracts were prepared from pyrB transformants, high levels of aspartate carbamoyltransferase activity were found, and the enzyme had properties identical to the mammalian enzyme, including lack of allosteric regulation, precipitation by antiserum specific to the hamster multifunctional protein, and presence of a strong aggregation center. These results demonstrate that (i) a partial hamster protein can complement E. coli defective in pyrimidine biosynthesis, (ii) the order of the enzyme domains of the multifunctional protein is likely to be NH2-dihydro-orotase-carbamoyl-phosphate synthetase-aspartate carbamoyltransferase-COOH, and (iii) the enzyme domains appear to be self-contained at the DNA and protein levels. The protocol described here may be a general means for studying the domains of multifunctional proteins and for isolating other mammalian genes for which bacterial mutants have been prepared. It also permits study of the structure and function of the same gene in both prokaryotic and eukaryotic cells and may provide new insight into the evolution of complex genes.
The first three enzymes of pyrimidine biosynthesis [carbamoyl- phosphate synthetase (CPSase; EC 6.3.5.5), aspartate carbamoyltransferase (aspartate transcarbamoylase; ATCase; EC 2.1.3.2), and dihydro-orotase (DHOase; EC 3.5.2.3)] in mammals are covalently linked on a multifunctional protein (1) (2) (3) designated CAD. The native protein is composed of an aggregate of three, four, or more identical monomers (1, 2, (4) (5) (6) . Each monomer is about 220,000 daltons in size (2, 3, 7) and is coded for by a 7.9-kilobase mRNA in hamster (8) . In previous studies, it has been shown that trypsin can cleave this protein into three pieces, each carrying a single enzyme activity (6) . Such data demonstrated that this protein is organized into independent functional domains, each the result of the folding of a local region of protein, and that the domains are separated from one another by protease-sensitive bridging sequences.
In Saccharomyces and Neurospora, only the first and second enzymes of pyrimidine biosynthesis are linked (9) (10) (11) (12) , the orientation being amino terminus-CPSase-ATCase-carboxyl terminus (10, 12) . Recently, an almost complete gene for the yeast protein was cloned into the plasmid pFL1 and was transformed into an Escherichia coli pyrB mutant (ATCase-) (13) . This plasmid did complement the E. coli mutant, although transformants were observed at a low frequency (1 in 108) .
In higher eukaryotes, such as Drosophila (14) (15) (16) (17) and Chinese hamster cells (ref. 6 ; unpublished data), the ATCase and DHOase domains have been shown to be at the termini of the CAD protein, but the orientation is unknown. A plasmid is available that contains a cDNA sequence corresponding to about 80% of a hamster CAD mRNA constructed in a special simian virus 40-pBR322 vector. Because this plasmid lacks the 5' end of the CAD coding sequence, it was reasoned that the enzyme domain encoded at the 3' end would be most likely to fold into its appropriate native structure and complement the appropriate E. coli mutant defective in pyrimidine biosynthesis. Here we describe the results of transforming an E. coli pyrB (ATCase-) mutant and an E. coli pyrC (DHOase-) mutant with the plasmid carrying a partial hamster CAD cDNA.
EXPERIMENTAL PROCEDURES Bacterial Strains. Mutant strains were kindly provided by B. Bachmann at the Coil Genetic Stock Center, New Haven, Conn. (18) . The pyrB mutant (no. 4517) is a uracil-requiring F-strain originally isolated by A. L. Taylor (AT 2535), whereas the pyrC mutant (no. 5358) is a uracil-requiring F-mutant developed by J. Beckwith (X7014a). E. coli strain HB101 (F-, proline-) and the plasmid pBR322 were used as controls.
Plasmid pCAD142. K. Shigesada and G. Stark have kindly provided us with the plasmid pCAD142. A 6.5-kilobase cDNA sequence synthesized from the 3' end of a Syrian hamster cytoplasmic CAD mRNA was constructed in pBR322 (K. Shigesada and G. Stark, personal communication) by using special simian virus 40 linkers (19) . This sequence contains a complete copy to the 3' end of the RNA including the poly(A) tail. In the protocol of Okayama and Berg (19) , the plasmid vector is missing the pBR322 sequence from the HindIII site (base pair 24) to the Pvu II site (base pair 2,065), which includes the entire tetracycline-resistance gene. A potential promoter for this gene might still be present in the vector (20, 21) , although separated by a 270-base-pair simian virus 40 linker from the cDNA insert. Whereas the CAD cDNA sequence is in the same 5'--3' orientation as the tetracycline gene it is replacing, it is missing 1.4 kilobases of sequence corresponding to the 5' end of the mRNA. The cDNA sequence is not of sufficient length to code for the entire CAD protein and must be missing the authentic initiation codon.
Transformation of the E. coli strains was carried out by using 
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a modification of the method of Dagert and Ehrlich (22) . The additional steps described below gave a greater efficiency of transformation (23) . Exponentially growing bacteria (20 ml) were centrifuged at 5,900 X g at 40C for 15 min, resuspended in 20 ml of 10 mM MgSO4, incubated on ice for 20 min, and centrifuged at 3,020 X g at 40C for 20 min. The bacteria were made competent by the CaCl2 steps described previously (22) (25) and 300 ,ug of ampicillin per ml or minimal M9 medium (25) lacking uracil and containing Vitamin B-1 (2.5 ,ug/ml), adenine (100 ,ug/ml), glucose (5 mg/ml), and 0.1% Casamino acids. DNA was extracted from randomly picked transformants (24) . Pst I restriction digests of the DNA were performed as described by the supplier (New England Biobabs) and electrophoresed on 0.75% horizontal agarose gels in Tris acetate buffer (26) . Preparation of Bacterial Cell Extract. Methods similar to that of Kantrowitz et al. (27) were used. Bacteria were grown in 25 ml of minimal M9 medium (25) supplemented with 0.1% Casamino acids, adenine (100 ug/ml), uracil (12 ,g/ml), and, if carrying a plasmid, ampicillin (50 ,ug/ml) for 18-20 hr at 37°C. Then 25 ml of fresh medium without uracil was added, and cells were grown for an additional 3 hr. Cells were pelleted at 10,000 X g for 10 min and resuspended in 2 ml of either 10 mM Hepes (pH 8.5) (for ATCase assay) or 10 mM Tris HCl (pH 7.4) (for DHOase assay). Cells were sonicated four times for 30 sec, and the supernatant was clarified at 30,000 X g for 10 min. Protein was determined by the Coomassie blue method (28-30) with Bio-Rad reagents.
Biochemistry. ATCase and DHOase assays were done by protocols previously described for assaying cell extracts from Chinese hamster cells (31, 32) . In experiments where allosteric effectors were used, effector and cell extract were mixed prior to adding other assay components. The method for immunoprecipitating CAD protein with hamster CAD-specific antiserum has been described (3). Instead of protein A sepharose, protein A Staphlococcus was used to bind the antibody-antigen complex. Native gel electrophoresis and assay of gel slices for ATCase activity were performed as described (6 were obtained as with selection on ampicillin, and all such transformants tested were resistant to ampicillin (Table 2) . On the other hand, very few pyrC cells grew in the absence of uracil, and none of these proved resistant to ampicillin. These pyrC uracil+ cells are likely to be revertants. When pyrB and pyrC cells were transformed with the plasmid pBR322 (which carries the ampicillin-resistant marker but not the hamster CAD cDNA) and selected on ampicillin, similar numbers of transformants were seen as observed in Table 1 except that none of the transformants tested were able to grow in the absence of uracil. The frequency of transformation of pyrB with pBR322
or pCAD142 was about 1:1 X 104. This6pyrB strain reverts to uracil+ at a frequency of about 1:3 x 10 . Thus, the frequency of uracil+ pyrB cells (after transformation) was 300 times higher than the frequency of reversion and is similar to the frequency of acquiring the plasmid pCAD142. Three cells were selected for further study: a pyrB[pCAD142] transformant originally selected on ampicillin (B142A-1), a pyrB[pCAD142] transformant originally selected in the absence of uracil (B.142P-1), and a pyrC[pCAD142] transformant originally selected on ampicillin (C142A-1). The two pyrB transformants are both ampicillin resistant and uracil+, whereas the pyrC transformant still has a uracil-phenotype.
Plasmid DNA was successfully isolated from each of these three transformants. Hence, although the pyrC[pCAD142] transformant does contain plasmid, this plasmid is apparently incapable of complementing the pyrC defect. The three purified plasmids were cleaved with Pst I, and the fragments were separated by agarose gel electrophoresis. Each plasmid yielded four fragments identical in size to the Pst I fragments of the original plasmid pCAD142 used in the transformations. Based on these results, there is no obvious change in the size of the plasmid after transformation into either pyrB or pyrC.
Secondary Transformation. Plasmid DNA purified from B142A-1 and B142P-1 was transformed into pyrB cells. Again regardless of whether selected in the presence of ampicillin or in medium deficient of uracil, large numbers of transformants were observed (Table 3) . Randomly picked colonies selected for ampicillin resistance were uracil+, and those selected for uracil+ were ampicillin resistant. Clearly, both properties are cotransferred and are coincident with uptake of the plasmid pCAD142. In parallel experiments, the frequency of secondary transformation was consistently 2-10 times higher than the frequency of primary transformation. It is a distinct possibility that modification of the plasmid by methylation during a first-time passage through the pyrB strain may provide protection against restriction when reintroduced into this strain.
Characterization (Table 4) . On the other hand, cell extract from pyrC and (3) . The discrepancy here is probably a consequence of the fact that the ATCase expressed in these trans- (3) .
Our previous experience with protease-treated CAD indicates-that a 39,000-to 42,000-dalton fragment with the ATCase activity also contains a strong aggregation center, which results in the formation of 15-or 16-mers (600,000-700,000 daltons) (36) . o, Extract from wild-type E. coli strain HblO; *, extract from transformant ,pyrB[pCAD142] selected in the absence of uracil. (6) . If the translation product of pCAD142 aggregated similarly, the ATCase activity associated with such an aggregate should migrate through a native polyacrylamide gel differently than the ATCase of E. coli. That this is indeed the case is demonstrated in Fig. 1 . The ATCase of E. coli Hb101 migrated on this native gel system as two peaks. The peak at 310,000 daltons represents the expected native form of enzyme with both catalytic (C) and regulatory (R) subunits (C6R6) (37, 38) . The peak at 110,000 daltons is likely the C3 form. The ATCase from a pyrB[pCAD142] transformant is of a very large size as expected for a highly aggregated hamster protein fragment. Thus, the translation product of pCAD142 contains not only the hamster ATCase active site but also the hamster CAD protein aggregation center.
DISCUSSION
These results clearly demonstrate that the plasmid pCAD142 can complement the defect in the E. coli strain pyrB and not in the pyrC -strain. Because the plasmid pBR322 eannot com--plement pyrB, it must be the partial cDNA to the hamster CAD protein that is responsible. The (6, (14) (15) (16) (17) Previous experiments with proteases indicated that the folded structure of the CAD protein was such that each of the three enzyme activities had to be associated with an independent, functional domain (6, 7). These domains appear linked together by regions of protein highly susceptible to proteases. This "string of beads" model proposes that each domain results from the folding of a local region of protein. In the experiments described in this paper, a partial cDNA sequence can lead to the proper folding and functioning of at least one enzymatically active domain of CAD. Thus, information at the amino terminus of CAD -is not required to generate an active ATCase domain. Hence, we propose that there might be at least three regions of information in the hamster CAD mRNA, each of which alone -might.yield a portion of protein capable of folding up and having an enzymatic activity. The organization of the processed hamster CAD mRNA may then be analogous to the RNA product expected if the E. coli genes pyrC (DHOase), pyrA (CPSase), and pyrB (ATCase) were fused together.
The closest bacterial structure similar to this RNA fusion product is the polycistronic messenger transcribed from an operon. In that case coordinate regulation leads to transcriptional control of one messenger and to translation of several protein products. Perhaps in the evolution of eukaryotes, gene fusions giving rise to monocistronic messengers and multifunctional proteins are an alternative to the bacterial operon as an effective means of coordinate regulation.
Whereas others (e.g., ref. 39 ) have shown that a plasmid carrying a cDNA to a mammalian gene can be expressed in E. coli, these experiments demonstrate that a plasmid carrying a mammalian cDNA sequence can even complement an E. coli defect. Furthermore, in the case here where the protein has a multidomain structure, it appears that even a partial cDNA sequence can function in bacteria. It might then be possible to use E. coli mutants defective in other bacterial genes in order to isolate the corresponding mammalian genes. For example, DNA from a cDNA library (19, 40) could be transformed into a particular E. coli mutant, and the complemented cell could be selected. In this way specific mammalian gene sequences could be purified biologically from a library.
